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Including pork in the Mediterranean diet
for an Australian population: Protocol for a
randomised controlled trial assessing
cardiovascular risk and cognitive function
Alexandra T. Wade1, Courtney R. Davis1, Kathryn A. Dyer1, Jonathan M. Hodgson2,3, Richard J. Woodman4,
Hannah A. D. Keage5 and Karen J. Murphy1*
Abstract
Background: The Mediterranean diet is characterised by the high consumption of extra virgin olive oil, fruits,
vegetables, grains, legumes and nuts; moderate consumption of fish, poultry, eggs and dairy; and low consumption of
red meat and sweets. Cross sectional, longitudinal and intervention studies indicate that a Mediterranean diet may be
effective for the prevention of cardiovascular disease and dementia. However, previous research suggests that an
Australian population may find red meat restrictions difficult, which could affect long term sustainability of the diet.
Methods: This paper outlines the protocol for a randomised controlled trial that will assess the cardiovascular and
cognitive benefits of a Mediterranean diet modified to include 2-3 weekly serves of fresh, lean pork. A 24-week cross-
over design trial will compare a modified Mediterranean diet with a low-fat control diet in at-risk men and women.
Participants will follow each of the two diets for 8 weeks, with an 8-week washout period separating interventions.
Home measured systolic blood pressure will be the primary outcome measure. Secondary outcomes will include body
mass index, body composition, fasting blood lipids, C-reactive protein, fasting plasma glucose, fasting serum insulin,
erythrocyte fatty acids, cognitive function, psychological health and well-being, and dementia risk.
Discussion: To our knowledge this research is the first to investigate whether an alternate source of protein can be
included in the Mediterranean diet to increase sustainability and feasibility for a non-Mediterranean population.
Findings will be significant for the prevention of cardiovascular disease and age-related decline, and may inform
individuals, clinicians and public health policy.
Trial registration: ACTRN12616001046493. Registered 5 August 2016.
Keywords: Mediterranean diet, CVD, Cognitive function, Randomised controlled trial
Background
As the population ages the prevalence and impact of
chronic age-related diseases and disorders is predicted
to increase dramatically [1]. In the elderly, dementia and
cardiovascular disease (CVD) are amongst the greatest
contributors to death and disability worldwide, and their
costs are expected to double and triple respectively over
the next 20 years [2–4].
Mediterranean populations in southern Europe, such
as Greece and Italy, exhibit significantly lower rates of
mortality from CVD and dementia than populations in
northern Europe and the United States [5]. It has been
suggested that this disparity is due to diverse dietary pat-
terns across populations, and that a Mediterranean diet
may be protective against CVD [6, 7]. As cardiovascular
health is a significant predictor of dementia [8, 9], the
Mediterranean dietary pattern may also be responsible for
lower rates of dementia.
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A traditional Mediterranean diet is characterised by a
high intake of extra virgin olive oil (EVOO), vegetables,
fruits, cereals, nuts, pulses and legumes; a moderate intake
of fish, poultry, dairy and red wine; and a low intake of eggs,
red and processed meat, and sweet and processed foods
[10]. The Mediterranean dietary pattern is therefore rich in
bioactive nutrients and phytochemicals such as monoun-
saturated fatty acids, polyunsaturated fatty acids (including
omega-3 s), polyphenols and flavonoids, vitamins, minerals,
antioxidants and fibre. Individually, these dietary compo-
nents are associated with improved cardiovascular health
[11–14]. However, single nutrients are not consumed in
isolation, but collectively as a dietary pattern. As such,
synergistic relationships between nutrients may en-
hance these benefits [15–17].
When compared with other dietary patterns a
Mediterranean diet has consistently improved indicators
of cardiovascular health. For example, a Mediterranean
diet has been shown to improve blood pressure, insulin
sensitivity, lipid profiles and markers of inflammation
[18–20], while reducing risk of cardiovascular events
by 30% [21].
Table 1 World Health Organisation Trial Registration Data Set
Data category Information
Primary registry and trial identifying number Australian New Zealand Clinical Trials Registry (ANZCTR) ACTRN12616001046493
Date of registration in primary registry 5 August, 2016
Secondary identifying numbers University of South Australia Human Ethics Committee 35,562. Pork CRC 3B-113.
Source(s) of monetary or material support Australian Pork Cooperative Research Council
Primary sponsor Dr Karen J Murphy
Secondary sponsors Alexandra T Wade, Courtney R Davis, Kathryn A Dyer, Jonathan M Hodgson,
Richard J Woodman, Hannah A.D. Keage
Contact for public queries Dr Karen J Murphy
Phone: +61 8202 2097. Email: Karen.Murphy@unisa.edu.au
Postal address: University of South Australia, GPO Box 2471, Adelaide SA 5001
Contact for scientific queries Dr Karen J Murphy, Senior Research Fellow, Dietitian, Alliance for Research in
Exercise, Nutrition and Activity, University of South Australia.
Phone: +61 8202 1033. Email: Karen.Murphy@unisa.edu.au
Postal address: University of South Australia, GPO Box 2471, Adelaide SA 5001
Public title Effect of a Mediterranean diet with fresh lean Australian pork on blood pressure,
cardiovascular risk factors and cognition, mood and psychological wellbeing
in high risk individuals
Scientific title Including pork in the Mediterranean diet for an Australian population: Protocol
for a randomised controlled trial assessing cardiovascular and cognitive outcomes
Countries of recruitment Australia
Health condition(s) or problem(s) studied Risk of cardiovascular disease (CVD)
Intervention(s) Active comparator: Mediterranean diet including fresh, lean pork
Control comparator: Low-fat diet
Key inclusion and exclusion criteria Inclusion criteria: adult (45-80 years) with elevated blood pressure
(>120 mmHg) with at least two other risk factors for CVD.
Exclusion criteria: antihypertensive medication, dietary
intolerances that may restrict consumption of intervention diets,
current CVD, type 2 diabetes mellitus, malignancy, liver, kidney,
gastrointestinal or respiratory disease, current diagnosis of
dementia or use of antidepressants, anxiety or neurological
medications
Study type Type: Interventional
Allocation: Randomised block allocation, parallel cross-over design
Primary purpose: prevention
Date of first enrolment 15 February 2017
Target sample size 31
Recruitment status Complete
Primary outcome(s) Home measured systolic blood pressure
Key secondary outcomes Body mass index (BMI), body composition, fasting blood lipids,
C-reactive protein, fasting plasma glucose, fasting serum insulin,
erythrocyte fatty acids, cognitive function, psychological health
and well-being, and dementia risk.
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While Mediterranean populations who follow a
Mediterranean diet exhibit lower risk of CVD and de-
mentia [15, 22–25], few studies have investigated
whether the diet can be successfully adopted in popula-
tions beyond the Mediterranean Sea. Notably, the
MedLey study examined the effects of a Mediterranean
diet over 6 months and found that an older Australian
population was capable of adopting the Mediterranean
diet [26]. However, participants indicated that one of the
most difficult aspects of following the diet was restrict-
ing red meat intake [27].
A traditional Mediterranean diet is typically low in
red meat products and Mediterranean dietary guide-
lines recommend consuming less than two serves of
red meat per week [28, 29]. A recent review has re-
ported that a traditional Mediterranean diet includes
105 g, or 0.5 to 0.75 standard serves of meat and
meat products per day [10]. This figure is inclusive
of all processed and unprocessed red and white meat
products. In contrast, Australians over the age of 19
consume an average of 184 g of meat per day, or 1.7
serves of lean meats and alternates, with red meat
contributing the largest proportion of this (38%)
[30]. Australians are amongst the highest consumers
of meat in the world [31]. Therefore, it is not sur-
prising that restricting red meat may prove difficult.
Countries with comparatively high meat intakes, such as
the United States and United Kingdom, may experience
similar difficulties (OECD, 2016). As socio-cultural norms
and palatability are key determinants of a dietary interven-
tion’s sustainability [32], non-Mediterranean populations
may then be more likely to adhere to a diet containing
more red meat.
Prospective cohort studies have drawn attention to
significant associations between red meat and poor
health outcomes, including bowel cancer and CVD
[33]. Proposed mechanisms point to the pro-oxidative
properties of heme iron found in red meat. However,
recent investigations highlight the mediating effects of
other dietary components on oxidation [34]. For ex-
ample, consuming EVOO with red meat has been
shown to attenuate lipid oxidation and the production
of free radicals [35]. When vitamin E, found in green
leafy vegetables and nuts, is consumed in combination
with EVOO and red meat, lipid oxidation is further
inhibited [35]. Moreover, the European Prospective
Investigation into Cancer and Nutrition (EPIC) study
reported significant interactions between red meat
and dietary fibre [36]. Specifically, individuals con-
suming red meat every day had a reduced risk of
developing colorectal cancer if they also consumed at least
26 g of dietary fibre each day – that is, less dietary fibre
than is provided by the Mediterranean diet [10]. The
potentially harmful effects of red meat may then be
mitigated when consumed within a Mediterranean
dietary pattern.
Australia’s most frequently consumed red meat
products are beef and pork [31]. In terms of nutri-
tional value, fresh lean beef and pork have similar nu-
trient profiles. However, fresh lean pork contains
considerably less heme iron than beef [37] and less
saturated fat per 100 g. Pork may then be an appro-
priate addition to a Mediterranean diet, which is typ-
ically low in saturated fat and heme iron sources [10].
Our previous research indicates that substituting beef
and chicken with pork may be effective for improving
cardiometabolic health markers, including weight,
body mass index (BMI), percentage body fat, fat mass
and abdominal fat, without negatively affecting blood
lipids, insulin or glucose [38]. Further, when com-
pared with ruminant meats such as beef and some
methods of aquaculture, pork production is associated
with significantly less agricultural greenhouse gas
emissions [39].
At present, there are no studies to our knowledge that
have investigated the substitution of meat protein
sources in the Mediterranean diet to increase variety
and sustainability for the target population and environ-
ment. The current study therefore aims to evaluate the
cardiovascular and cognitive benefits of a Mediterranean
diet, supplemented with fresh, lean pork against a low-
fat diet. A low-fat control diet has been chosen due to
its continued recommendation for the clinical manage-
ment and reduction of cardiovascular risk [40]. Further,
including a low-fat control will enable comparisons of
our findings against larger studies of the same design,
such as the Prevención con Dieta Mediterránea (PRE-
DIMED) trial. Due to the pressing need to reduce the
impact of CVD and dementia, the modified Mediterra-
nean diet will be evaluated for its potential to improve




Details of the current study protocol are provided in
Table 1. Volunteers aged between 45 and 80 who are at
risk of developing CVD will be recruited via electronic
and paper advertisements.
To meet eligibility criteria, volunteers must have el-
evated systolic blood pressure above 120 mmHg and
at least two other risk factors for CVD, including: a
BMI ≥ 25 kg/m2; elevated fasting total cholesterol
(≥5.5 mM), triglycerides (≥2.0 mM), low-density lipo-
protein (LDL) (≥3.5), or low levels of high-density
lipoprotein (HDL) (≤0.9 for men and ≤1.0 for
women); impaired fasting glucose tolerance (between
6.1 and 7.8 mmol/L); and/or a family history (up to
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one generation) of CVD or type 2 diabetes mellitus
(T2DM). Exclusion criteria include: antihypertensive
medication; smoking; current CVD or angina; current
or recent (within 6 months) malignancies; respiratory dis-
ease; gastrointestinal disease; kidney disease; T2DM; a
current or previous traumatic head or brain injury; a
current neurological or psychiatric condition; anti-
depressant or anxiety medication; a current diagnosis
of Alzheimer’s disease or dementia; or supplemental
omega-3 > 1000 mg daily.
Eligibility will be assessed through a diet and life-
style questionnaire (DLQ) and screening visit at the
Sansom Institute for Health Research Clinical Trial
Facility (SIHR CTF), Adelaide, South Australia. The
DLQ includes medical history, medications and sup-
plements, family medical history, and dietary aver-
sions, allergies and intolerances. Volunteers deemed
eligible on the basis of their DLQ will be screened
to measure systolic blood pressure, diastolic blood
pressure, heart rate, height and weight, fasting cholesterol
and fasting glucose. The Addenbrooke’s Cognitive
Exam-Revised (ACE-R) will also be administered to
detect pre-existing dementia and mild cognitive im-
pairment (MCI).
Design
A 24-week cross-over design trial will compare a
Mediterranean diet intervention with a low-fat diet
intervention. Each participant will complete both
dietary interventions for 8 weeks and the two inter-
vention phases will be separated by an 8-week wash-
out period (See Fig. 1). An independent staff member
of the SIHR will perform the block randomisation
procedure. Participants will be allocated to one of
two groups using, stratified by age and gender, to
determine the order in which they undertake the in-
terventions. Allocation concealment will ensure that
study personnel and volunteers are not aware of the
starting intervention prior to enrolment. During the
washout period participants will return to their habit-
ual diet to prevent cross-contamination of effects be-
tween dietary phases.
By reducing potential between-subject differences a
cross-over design reduces the effects of potential
confounding variables, and therefore enhances in-
ternal validity of the design. Further, performing re-
peated measures on the same individual allows for an
estimation of an individual’s true value, measurement
error and treatment effect, meaning that fewer partic-
ipants will be required to detect a treatment effect.
An 8-week intervention period has been chosen as
randomised controlled trials (RCTs) of similar length
have found that nutrients contained within the
Mediterranean diet can improve both cardiovascular
and cognitive function [41–43]. Eight weeks is ex-
pected to be an adequate washout period [44]. How-
ever, potential carryover effects will be assessed by
testing for intervention*phase interactions.
Dietary interventions
Neither diet will restrict energy intake. Instead, partici-
pants will be advised to self-regulate their food intake
and consume foods ad-libitum.
Low-fat diet
Guidelines for the low-fat diet are based on the PRE-
DIMED study, which compared two variations of a
Mediterranean diet with a low-fat control diet [45].
Participants will be advised to make adjustments to
their habitual diet in order to reduce total fat intake.
Specifically, high fat foods, including all types of oil,
butter, margarine, processed and high fat meats, nuts,
chocolates, cakes, pastry, and high or full fat dairy,
will be replaced with low-fat alternatives, such as
breads and cereals, legumes, rice, fruits and vegetables
and low-fat varieties (e.g. low-fat dairy, low-fat
sauces). Daily limits will be set for oil (no more than
20 ml), butter and margarine (no more than two tea-
spoons), and participants will be instructed to remove
visible fat and skin from meat and fish before
cooking.
Mediterranean diet
Guidelines for the Mediterranean diet are adapted










Phase 1 Phase 2
Week 0 8 16 24
Fig. 1 Title: 24-week cross-over design trial
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 Minimum of one tablespoon (20 mL) of EVOO per
day;
 ≥2–3 daily servings of fresh fruit (one serve =
150 g fresh, 30 g dried, or one cup canned in
natural juice);
 ≥3 weekly servings of legumes (one serve = 75 g);
 2-3 weekly servings of fresh, lean pork (one serve =
100 g cooked)
 ≥3 weekly servings of fish and seafood (at least one
serving of oily fish) (one serve = 100 g cooked);
 ≥5 weekly serving of raw or roasted nuts or seeds,
without added salt, sugar or chocolate (one serve =
30 g; 7.5 g hazelnuts, 15 g walnuts, 7.5 g almonds
supplied for each serve);
 Ad-libitum consumption of wholegrain cereal
products (bread, pasta, rice, cereal) and dairy
 Ad-libitum consumption of eggs, not to exceed 6
serves per week (1 serve = approx. 70 g or 1 egg)
 Select white meats (poultry without skin) instead of
red meats or processed meats;
 Limit consumption of red and cured meat (remove
all visible fat) to ≤1 serve/week (one serve of red
meat/cured ham = 100 g);
 Limit consumption of chocolate to ≤1 serve/week
(one serve of chocolate = 50 g);
 Use EVOO for cooking and dressing vegetables and
salad;
 Cook regularly (at least twice a week) with a tomato
based sauce (EVOO, tomato, garlic and onion);
 Dress vegetables, pasta, rice and other dishes with
EVOO, tomato, garlic and onion sauce;
 Eliminate or limit the consumption of cream, butter,
margarine, cold meat, pate, duck, carbonated and or
sugared beverages, pastries, commercial bakery
products (cakes, donuts, cookies), desserts
(puddings), French fries, potato crisps, sweets;
 For usual drinkers, red wine is recommended as the
main source of alcohol with a maximum of two
standard drinks per day (200 mL = two standard
drinks) [46]
Participants will be advised to consume pork in place
of chicken and red meat ensure that total meat con-
sumption does not exceed 400 g per week.
To assist with adherence, the following foods will be
provided each week: 375 ml EVOO; 250 g of fresh, lean
pork; 150 g raw, unsalted almonds, walnuts and hazel-
nuts; 225 g (net weight) of canned chickpeas, red kidney
beans, 4-bean mix and lentils; 95 g of canned tuna and
95 g of canned salmon.
Dietetic counselling
To increase adherence and retention participants will
have regular contact with a dietitian. At the beginning
of each phase, participants will meet with the dietitian to
discuss dietary guidelines in detail. For the Mediterranean
diet, participants will be provided with a set of re-
sources, including Mediterranean dietary guidelines
(Appendix 1), recommendations on how to include
pork in the diet (Appendix 2), education on serving
sizes and a Mediterranean diet recipe book. For the
continual assessment of adherence, and to encourage
familiarity of foods and serving sizes associated with a
Mediterranean diet, participants will also be given a
semi-quantitative checklist (Appendix 3) to be filled
in daily, using a tick system (1 tick = 1 serve), and
returned at bi-weekly dietetic visits. While on the
low-fat diet, similar dietetic resources will be provided,
including a set of low-fat diet guidelines (Appendix 4),
education on fat content and a food label reading
guide (Appendix 5) to consider when selecting pack-
aged foods.
Throughout each intervention phase participants
will attend bi-weekly dietetic visits to discuss their
progress, food intake, challenges and any adverse ef-
fects. These visits will also include weight measure-
ment to determine body mass, weight loss or weight
gain. In the case of weight loss or gain the dietitian
will ensure that participants are eating until satiated
and discuss mindful eating and portion sizes. If a par-
ticipant is having trouble adhering to the guidelines
the dietitian will discuss strategies and work with the
participant to set SMART goals (S, specific; M, mea-
sureable; A, achievable; R, realistic; T, time based) for
the next 2 weeks.
Outcome measures
Home blood pressure
Home measured systolic blood pressure will be the primary
outcome measure. For the reliable assessment of hyperten-
sion, home measured blood pressure is comparable to am-
bulatory blood pressure, and has stronger predictive power
than clinic blood pressure [47–49].
Participants will receive training on self-administered
blood pressure measurement and will be instructed to
measure their systolic and diastolic blood pressure and
heart rate every morning, afternoon and evening for 6
days at the four assessment points over the course of the
trial. Participants will be provided with a clinically vali-
dated A&D Company Ltd. digital blood pressure moni-
tor (model UA-767). Measurements will be taken at a
consistent time each day after a five-minute rested
period in the seated position. Three consecutive readings
are to be taken spaced at least 1 min apart, as per
Bondonno et al. (2015) and participants will be advised
to avoid caffeine and alcohol for 1 h prior to measure-
ment, and food and exercise for 30 min prior.
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Secondary outcome measures and covariates
Over the four assessment time points, home measured
diastolic blood pressure and heart rate, clinic blood pres-
sure and heart rate, BMI, waist-to-hip ratio, body com-
position, fasting blood lipids, C-reactive protein (CRP),
fasting plasma glucose, fasting serum insulin, erythrocyte
fatty acids, cognitive function, psychological health and
well-being, and dementia risk will be examined as sec-
ondary outcomes.
Clinic blood pressure will be measured using an
Omron Healthcare Co. digital blood pressure monitor
(model 1A1B Hem-7000-CIL). The same protocol as
for home blood pressure measurement will be
followed, where participants will be seated for 5 min
and three measurements will be taken spaced at least
1 min apart. Waist and hip circumference will be mea-
sured to determine waist-to-hip ratio. Body compos-
ition, including percentage body fat, lean mass and
abdominal adiposity will be measured using dual-
energy x-ray absorptiometry (DEXA). Fasting venous
blood will be collected through venepuncture and ana-
lysed at an external NATA accredited laboratory using
standard procedures. Erythrocyte fatty acids will be
measured using direct transesterification as described
by Tu et al. (2013) once further funding has been
secured. Whole blood will be centrifuged (4 °C,
4000 rpm, 10 min) to separate erythrocytes from spare
plasma, both of which will be frozen at −20 °C and
then stored at −80 °C. APOEε4, an indicator of in-
creased risk for AD, will be determined using the
TaqMan® SNP Genotyping assay kit (Applied Biosys-
tems, Warrington, UK) [50]. For explorative purposes,
a faecal sample will also be collected to examine the
effects of a Mediterranean diet on gut microbiota. Faecal
samples will be frozen at −20 °C and then stored at −80 °C
until further funding has been secured.
Cognitive function will be assessed across memory,
processing speed and executive function using a selec-
tion of tests from the Cambridge Automated Neuro-
psychological Test Automated Battery (CANTAB).
These particular cognitive domains will be examined
due to their vulnerability to aging and cardiovascular
health, and their demonstrated sensitivity to short term
nutritional interventions [51–56]. The battery of tests
will include Motor Orientation Task (MOT), Paired
Associates Learning (PAL), Delayed Matching to Sample
(DMS), Verbal Recognition Memory (VRM), Reaction
Time (RTI), Rapid Visual Information Processing
(RVIP), Spatial Working Memory (SWM), One Touch
Stockings of Cambridge (OTS) and Attention Switching
Task (AST).
A computerised mode of testing has been chosen to
increase accuracy and reliability, especially where sensi-
tivity to processing speed is critical [57]. To limit the
effect of learning over repeated measures, the CANTAB
offers parallel versions of each test. For the chosen tests,
test re-test reliability (r) ranges from r = 0.54 (RTI) to
r = 0.87 (PAL) [58]. To examine potential measurement
error, especially where the test-retest coefficient is less
than r = 0.7, learning effects can be determined using
standardised scores and standard errors provided by
Cambridge Cognition [58].
The Karolinska Sleepiness Scale (KSS) will be adminis-
tered prior to cognitive testing to gain insight into sleep
quality and sleepiness, which may impair cognitive func-
tion. The KSS is a 9-point scale that asks participants to
rate their current level of sleepiness where 1 = Extremely
alert, 2 = Very alert, 3 = Alert, 4 = Rather alert, 5 = Neither
alert nor sleepy, 6 = Some signs of sleepiness, 7 = Sleepy,
but no effort to keep awake, 8 = Sleepy, some effort to
keep awake, 9 = Very sleepy, great effort to keep awake,
fighting sleep. The KSS has been validated against
electroencephalography (EEG) and behavioural measures
of sleepiness [59]. A score of 6 and above on the KSS
has been linked to significant increases in reaction
time and lapses on a psychomotor vigilance task, and
decreased levels of arousal as measured by the alpha
attenuation test [59].
To screen for dementia and MCI, and to detect change
in cognitive function associated with dementia and MCI
(attention, orientation, memory, fluency, language and
visuospatial abilities), the ACE-R will be administered
during screening visits and at the end of each dietary
phase [60]. The ACE-R is frequently used in clinical and
research settings, with high sensitivity and specificity for
detecting both dementia and MCI.
Future risk of dementia will be calculated using
the Cardiovascular Risk Factors, Aging and Dementia
(CAIDE) score, and the Framingham vascular risk
score (FRS) [61]. The CAIDE predicts 20-year de-
mentia risk based on middle age profiles with high
sensitivity (0.81) and moderate specificity (0.61). The
CAIDE score is based on age, sex, education, total
cholesterol, systolic blood pressure, physical activity
and APOEε4 genotype. Similarly, the FRS determines
risk of CVD on the basis of age, sex, systolic blood
pressure, hypertension, HDL cholesterol, total chol-
esterol, smoking status and diabetes [62]. Although
originally developed to predict risk of vascular dis-
ease, the FRS reliably predicts decline in cognitive
function and has demonstrated stronger associations
than the CAIDE with 10-year risk of cognitive
decline [10].
Psychological well-being, an outcome and determin-
ant of health behaviours, will be evaluated through the
SF-36 Health Survey Version II adapted for use in
Australia [63] and the Profile of Mood States (POMS).
The SF-36 and POMS have been chosen for their
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relevance to a non-clinical population. The SF-36 was
designed to measure subjective perceptions of health
status across the domains of vitality, physical function-
ing, bodily pain, general health perceptions, physical
role functioning, emotional role functioning, social role
functioning and mental health [64]. The Australian SF-
36 has demonstrated high internal consistency and reli-
ability, adequate test-retest reliability and sensitivity to
change, including sensitivity to nutritional interventions
[65, 66]. The POMS measures mood states of tension,
anxiety, anger, hostility, vigour, activity, fatigue, inertia,
depression, dejection, confusion and bewilderment by
asking participants to rate the extent to which they
have recently felt different emotions [67]. For the pur-
pose of the proposed study, participants will be asked
about the extent to which they have felt emotions over
the past month. The POMS has demonstrated good
internal consistency (Cronbach’s alpha = 0.63 to 0.96)
and test re-test reliability of r = 0.61 to r = 0.69 at
6 weeks [68].
Dietary adherence
A 15-item Mediterranean diet adherence survey and a 9-
item low-fat diet adherence survey (Appendix 6) will be
administered to participants bi-weekly to capture gener-
alised patterns of food consumption during each of the
intervention phases. Each survey has been adapted from
the PREDIMED study to reflect an Australian food sup-
ply and national guidelines for alcohol consumption.
While on the Mediterranean diet, participants will
also complete a semi-quantitative weekly checklist
(Appendix 3, described above). Adherence to the diet-
ary phase will be determined at each bi-weekly visit, where
participants must meet a minimum adherence requirement
of 75%, as determined by checklists. If participants scoring
below 75% are unable to increase their adherence in the
next 2 weeks they will be excluded from the study.
To determine the impact of dietary adherence on out-
comes an overall Mediterranean diet score [15, 26] will
be calculated using data from a 3-day weighed food rec-
ord (WFR) completed by participants before and at the
end of each intervention phase. Further, erythrocyte
fatty acids will provide a biological measure of dietary
adherence at the end of each intervention phase.
Exit survey
At the end of each intervention an exit survey will be
administered to capture further insight and qualitative
information about participant perceptions of the diets.
The surveys will ask participants to elaborate what they
enjoyed and found challenging about the diet they have
just completed. To measure hunger and satiety experi-
enced during each intervention the survey will also include
five questions based on the 5-Factor Satiety Questionnaire
[69] with corresponding visual analogue scales (VAS). Par-
ticipants will be asked to indicate 1) “How hungry did you
feel after you finished a meal?”, 2) “How full did you feel
after you finished a meal”, 3) “How satisfied did you feel
after you finished a meal?”, 4) “How strong was your desire
to eat after you finished a meal?” and 5) “How much more
could you have eaten after you finished a meal?”. For
questions 1-4, the VAS will range from “Not at all” to
“Extremely”, and for question 5 the VAS will range from
“Nothing at all” to “A very large amount”.
Procedure
Data will be collected by participants at home and by
study personnel during clinic assessment visits at the
SIHR CTF across the course of the trial (See Fig. 2).
Participants will attend a pre-baseline appointment at
the SIHR CTF where the study will be explained and
informed consent will be obtained by study personnel
(Appendix 7). Instructions and equipment will be given
for the collection of home measures, including blood
pressure, SF-36, POMS and WFR. Participants will then
return 1 week later for week 0 assessments.
Clinic assessment visits will take place at baseline of the
first diet (week 0), at the end of the first diet (week 8), at
baseline of the second diet, after the 8-week washout
period (week 16), and at the end of the second diet
(week 24). Data for home measures will be collected
by participants in the week prior to each of these visits.
At clinic assessment visits participants will be fasted
from food, beverages (excluding water), alcohol and
caffeine for 12 h. Clinic assessment visits will include
measurement of blood pressure, body anthropometry,
DEXA and collection of fasted blood samples. At weeks
0 and 16 participants will be allocated to their diet and
meet with a dietitian to discuss the dietary guidelines.
Participants will then be given a continental breakfast
before cognitive tasks are administered. To minimise the
impact and influence of external variables, cognitive test-
ing conditions will be rigorously controlled and standar-
dised as outlined by [70]. All cognitive testing sessions
will take place between 9:30 am and 12:00 pm. To limit
the impact of food intake on cognitive performance, par-
ticipants will consume the same breakfast before each
cognitive session.
If participants have performed a strenuous level of
non-habitual exercise in past 10 h, not had an adequate
amount of sleep, or are unusually tired cognitive assess-
ments will be rescheduled. Temperature and noise of
the cognitive testing environment will be controlled in
order to reduce distraction and test administration will
be standardised through the use of a testing script
provided by Cambridge Cognition. Participants will
commence the dietary intervention on the day following
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week 0 and week 16 visits, and will commence the wash-
out period on the day of the week 8 visit.
Between weeks 0 and 8, and 16 and 24 participants
will attend bi-weekly dietetic visits at the SIHR CTF. In
the final dietetic visit of each diet phase, and at week 15,
participants will be provided with equipment for the
collection of home measures to be returned at their next
clinic assessment visit.
Volunteers will be instructed to continue any habitual
exercise and medications for the duration of the trial.
Changes to exercise and medications will be monitored
and recorded at bi-weekly dietetic visits and clinic as-
sessment visits by the investigators.
Statistical analysis
Statistical analyses will be conducted using SPSS for
Windows, version 21.0 (SPSS Inc., Chicago, IL, USA)
and Stata (version 14.2, StataCorp, College Station, TX,
USA). Data will be presented as means ± standard devi-
ation (SD) for descriptive statistics and as means ±
standard error (SEM) for reporting estimated effects. All
tests will be 2-tailed with p-values <0.05 deemed statisti-
cally significant.
Based on power calculations, a sample size of 31 vol-
unteers is required to detect a clinically relevant differ-
ence of 2.5 mmHg in home blood pressure, the primary
outcome measure, with power of 90%. This calculation
accounts for a total of 54 readings (three readings taken
three times per day for 6 days) at each time point, a
within-group standard deviation of 14 mmHg, a within-
subject repeated measures correlation of r = 0.6 and a
between-phase within-subject correlation of ρ = 0.5. The
correlation (ρ) and use of a cross-over design reduces the
number of required participants by a factor of (1 − ρ)/2 = 4
[153] i.e., from approximately n = 124 for a parallel group
design using ANCOVA (n = 62 per group) to n = 31 sub-
jects in total.
Baseline demographic, cardiometabolic, cognitive, well-
being and dietary characteristic data will be compared for
those who complete the study and those who withdraw
using independent t-test and chi-square tests, depending
on the type of variable and distribution of data.
Fig. 2 Title: Schedule of enrolment, interventions, and assessment. Legend: *Bi-weekly. Med diet, Mediterranean diet; LF, low-fat diet; BP, blood pressure;
POMS, Profile of Mood States; SF-36, Short Form-36 Health Survey; WFR, weighed food record; CRP, C-reactive protein; RBCFA, red blood cell fatty acids
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The primary analysis will be performed on a per
protocol basis including only those subjects who
complete both trial phases. A linear mixed effects model
will determine the difference in each outcome between
dietary interventions and will measure both between and
within subject effects for cardiometabolic and cognitive
outcomes. If a significant change is detected for cogni-
tive outcomes a hierarchical regression will include car-
diometabolic outcomes to assess their meditating effects.
A sensitivity analysis will include weight loss, change in
physical activity, medications and supplements as these
may cause time-varying confounding should they differ
between groups in the second dietary phase. Further,
carryover and treatment-period effects will be assessed
by including treatment*phase and treatment*order inter-
action terms. A diet*period*energy intake interaction
term will be included to determine any significant
changes between diets in relation to total energy intake,
macronutrient intake and micronutrient intake. As an
additional sensitivity analysis we will also include sub-
jects that did not complete the trial or were not included
in the per protocol analysis due to inadequate adherence
(<75%). For missing data the linear mixed effects models
will estimate unbiased effects as opposed to multiple
imputation.
Trial and data management
To ensure privacy and confidentiality each participant
will be assigned a unique study identification (ID)
number. All source documents will be de-identified
(re-identifiable by coded ID numbers) and stored in an
individual file for each study participant. All information
collected as part of the study will remain confidential and
no information that could lead to identification of any
individual will be released. Access to trial data will be
limited to the team of investigators named as authors on
this publication.
Unintended effects and adverse events of the trial
intervention will be identified during bi-weekly dietetic
visits. All adverse and serious adverse events will be re-
corded and serious adverse events will be reported by
the Chief Investigators to the University of South
Australia Human Research Ethics Committee. Partici-
pants will be advised to consult with their General Prac-
titioner regarding any notable symptoms identified
throughout the trial. If the instance of adverse events a
decision to continue, modify or cease the intervention
will be made on a case-by-case basis.
Due to the size of the trial and nature of the trial inter-
vention a Data Monitoring Committee is not deemed
necessary. The Chief Investigator will conduct quality
control checks of data values twice during each dietary
intervention phase to ensure data quality.
Electronic data entry will be completed throughout
the trial by study personnel. Electronic data files will be
stored on a secure password protected network and
backed up regularly on an external hard drive. Once the
trial is complete and results have been published elec-
tronic files will be stored on a DVD in the Sansom
Clinical Trials facility secure data store in the Bonython
Jubilee Building, City East Campus. Study documenta-
tion will be kept in locked filing cabinets within in the
Sansom Clinical Trials facility in the Bonython Jubilee
Building, City East Campus. Once the study is complete
and results have been published all data will be archived
and stored for a total of 15 years.
Any changes to the trial protocol will require approval
by all authors and the University of South Australia
Human Ethics Committee. Once approved, modifica-
tions to the trial protocol will be communicated to the
funding sponsors and the journal wherein the protocol
is published.
Results from this trial will be disseminated through
peer-reviewed international journals, presentations at
national and international meetings and the lead author’s
doctoral dissertation. Participants will be provided with
a copy of their personal results within 6 months of com-
pleting the study and a summary of the research findings
will be sent to all participants once data analysis has
been completed.
Discussion
To reduce the impact of both dementia and CVD health
and lifestyle interventions with the potential to mitigate
multiple risk factors have been recommended above
reactive, costly treatments [71, 72]. Risk factors such as
hypertension, dyslipidaemia, insulin sensitivity are shared
by both dementia and CVD [73–76]. Interventions target-
ing each of these simultaneously may be effective in redu-
cing the prevalence of both CVD and dementia.
However, it is necessary to ensure that such interven-
tions are sustainable, both for the target population
and the environment.
The Mediterranean diet has demonstrated efficacy for
reducing risk of CVD and cognitive decline. Yet an
Australian population, who typically consumes a high
quantity of meat, may find adhering to the meat restric-
tions of the diet difficult. This paper outlines the proto-
col of a randomised controlled trial that endeavours to
compare a Mediterranean diet with an additional source
of meat protein, against a low-fat control diet. Findings
of the forthcoming study will be relevant at a policy,
clinical and individual level and will provide insight as to
whether consuming pork as a part of a Mediterranean
diet can improve health outcomes while simultan-
eously increasing variety and sustainability for the
target population.
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Appendix 1
Fig. 3 Guidelines for the MedPork intervention
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Appendix 2
Fig. 4 Recommendations for including pork in the Mediterranean diet
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Appendix 3
Fig. 5 Semi-quantitative weekly checklist to encourage adherence to the MedPork intervention
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Appendix 4
Fig. 6 Guidelines for the LF intervention
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Appendix 5
Fig. 7 Dietetic resource for reading food labels while following the LF intervention
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Appendix 6
Fig. 8 9-item Low Fat diet adherence survey and 15-item Mediterranean
diet adherence survey
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